SCHEMBL1503889

SCHEMBL1503889

N[C@@H]1COC[C@H]1N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2030394 1.00
SCHEMBL14817860 1.00
SCHEMBL1503838 1.00
SCHEMBL1988050 1.00
Hydrochloric Acid SCHEMBL1504074 0.96
Hydrochloric Acid SCHEMBL21240457 0.96
Hydrochloric Acid SCHEMBL14844672 0.96
Hydrochloric Acid SCHEMBL21240455 0.96
Hydrochloric Acid SCHEMBL16655313 0.96
Hydrochloric Acid SCHEMBL14844671 0.96

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4326740-A1 PEPTIDE NUCLEIC ACIDS, SYNTHESIS, AND USES THEREOF Ongogenuity, Inc. (US) 2024-02-28 EP disclosed
CN-114751897-A Zinc guanidyl complex catalyst, preparation method and application thereof 烟台大学 2022-07-15 CN disclosed
US-9951079-B2 Fused tricyclic heterocyclic compounds as HIV integrase inhibitors MERCK SHARP & DOHME CORP. (US) 2018-04-24 US disclosed
US-9951079-B2 Fused tricyclic heterocyclic compounds as HIV integrase inhibitors MERCK SHARP & DOHME CORP. (US) 2018-04-24 US disclosed
US-20170305923-A1 FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-10-26 US disclosed
US-20170305923-A1 FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-10-26 US disclosed
EP-2763975-B1 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS MERCK SHARP & DOHME (US) 2016-04-06 EP disclosed
US-8987456-B2 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors MERCK SHARP & DOHME CORP. (US) 2015-03-24 US disclosed
US-8987456-B2 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors MERCK SHARP & DOHME CORP. (US) 2015-03-24 US disclosed
US-8987456-B2 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors MERCK SHARP & DOHME CORP. (US) 2015-03-24 US disclosed
US-20050124671-A1 Benzylcycloalkyl amines as modulators of chemokine receptor activity WACKER DEAN A (US) 2005-06-09 US disclosed
US-20050119486-A1 Diamine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2005-06-02 US disclosed
US-6864380-B2 Benzylcycloalkyl amines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-03-08 US disclosed
US-20050020645-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-27 US disclosed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 EP disclosed
US-20040014758-A1 Benzylcycloalkyl amines as modulators of chemokine receptor activity WACKER DEAN A (US) 2004-01-22 US disclosed
US-6608227-B1 Prevention of inflammatory diseases such as asthma and other allergic diseases BRISTOL-MYERS SQUIBB PHARMA 2003-08-19 US disclosed
CN-1056612-C Process for epoxidation of prochiral olefins, catalyst for use in the process SMITHKLINE BEECHAM PLC (GB) 2000-09-20 CN disclosed
CN-1145623-A Process for epoxidation of prochiral olefins, catalyst for use in the process and intermediates for making the catalyst SMITHKLINE BEECHAM PLC (GB) 1997-03-19 CN disclosed